Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.34 AUD
Change Today -0.015 / -4.29%
Volume 5.7M
As of 2:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/20/15 - A$0.45
52 Week Low
11/19/14 - A$0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which include super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which include Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, including glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: A$332.8K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Chief Scientific Officer
Total Annual Compensation: A$200.0K
Compensation as of Fiscal Year 2014.

novogen ltd (NRT) Key Developments

Novogen Signs Memorandum of Understanding with Feinstein Institute for Medical Research

Novogen announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research to collaborate with the objective of developing effective treatments for brain cancers. At the heart of the collaboration is the company's super-benzopyran (SBP) drug technology platform, distinguished by its ability to kill the full spectrum of cells within a tumor including both rapidly- and slowly-dividing cancer cells (tumor-initiating cells). The three key areas of research will be: the development of lead SBP drug candidate, TRXE-009, as a treatment of both primary and secondary brain cancer in adults and children, including glioblastoma and medulloblastoma; the potential ability of the SBP technology (based on early evidence) to deliver an entirely novel approach to chemotherapy by converting cancer stem cells into stem cells displaying normal stem cell behaviour; and the development of drug candidates as radio-sensitizers designed to augment the effectiveness of radiotherapy in treating brain cancers. TRXE-009 (Trilexium) is a pan-acting (across all forms of cancer) anti-cancer cytotoxic molecule that is on track to enter the clinic in early-2016 for the treatment of solid and non-solid cancers. A particularly high activity against melanoma cells has been announced previously and malignant melanoma is expected to be a key clinical indication to be pursued. For this purpose, TRXE-009 will be delivered systemically in a way that the company has confirmed in animal studies delivers the drug in a bio-available form in the bloodstream that delivers a potent anti-tumor effect on tumors growing outside of the brain. The task now remains to confirm that TRXE-009 can be delivered to brain cancer tissue in adequate amounts. TRXE-009 has proven to be particularly effective in vitro against adult (glioblastoma) and paediatric (diffuse intrinsic pontine glioma; medulloblastoma) brain cancer cells, marking it as a unique and highly promising drug candidate for the treatment of these cancers. The collaboration announced is focused specifically on these tumors and the need to optimize the delivery of TRXE-009 to cancerous tissue within the brain. Using models developed in the laboratory by the Feinstein Institute, the ability of TRXE-009 to treat various forms of human brain cancer will be studied using a variety of new approaches, such as direct micro-injection into the brain (convection enhanced delivery) and intravenous administration with a range of constructs known to facilitate the transport of drugs across the blood-brain barrier, some of which have been developed by Novogen chemists.

Novogen Announces Updates on Oncology Pipeline Drug Candidates, Anisina (ATM-3507)

Novogen has announced that one of its oncology pipeline drug candidates, Anisina (ATM-3507), confirmed the concept that comprehensive destruction of a cancer cell’s cytoskeleton can deliver a powerful anti-cancer effect. The cytoskeleton (cell skeletal structure) is a common and validated target for anti-cancer therapy. The most commonly used drugs in chemotherapy target the cytoskeleton by destabilising one of its two key components, the microtubules. These drugs are known as ‘anti-mitotics’ and include the taxanes (paclitaxel, docetaxel) and the vinca alkaloids (vincristine, vinblastine). Collectively, these anti-mitotics have dominated chemotherapy for the past 30 years and look set to do so for many years to come. The rationale behind the development of Anisina was that the anti-mitotic drugs only do half the job, because they leave the other major component of the cytoskeleton, the microfilaments, intact. It was reasoned that this half-complete destruction of the cytoskeleton by the anti-mitotic drugs accounted for their low rate of patient response for many tumor types and for the generally short-term response to therapy. Anisina was developed specifically to destroy the microfilaments and to work in combination with the anti-mitotic drugs to deliver comprehensive destruction of the cancer cell’s architecture. Anisina targets a specific protein known as tropomyosin Tpm3.1 (previously known as Tm5NM1). Tpm3.1 is a protein that provides structural integrity to the microfilaments of a cell. It is present in both normal cells and cancer cells, the difference being that cancer cells have an increased reliance on this form of tropomyosin to survive. It has been announced previously that anti-tropomyosin drugs in combination with anti-mitotic drugs boost the cancer-killing ability of a drug such as vincristine 20-fold in vitro against neuroblastoma cancer cells. The next crucial step was to confirm that this powerful combined anti-cancer effect was transferable to animals.

Novogen Limited Announces Consolidated Earnings Results for the Half-Year Ended December 31, 2014

Novogen Limited announced consolidated earnings results for the half-year ended December 31, 2014. For the period, revenue was $5,565 against $29,206 a year ago. Loss before income tax expense was $2,434,394 against $3,069,898 a year ago. Loss for the half-year is attributable to owners of the company was $2,247,407 against $3,055,263 a year ago. Basic and diluted earnings per share were 1.274 cents against 2.108 cents a year ago. Net cash used in operating activities was $1,475,630 against $2,100,814 a year ago. Payments for property, plant and equipment was $4,272 against $11,357 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.34 AUD -0.015

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies

Industry Analysis


Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.2x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at